Please join us for our fourth quarterly call and year end update of 2017 today, April 5, 2018, 4:30pm ET.
Please join us for our fourth quarterly call and year end update of 2017 on April 5, 2018 at 4:30pm.
TapImmune President and CEO, Peter Hoang, to present at 2018 The Microcap Conference.
TapImmune Announces Publication of Clinical Trial Results for the TPIV200 Cancer Vaccine in Clinical Cancer Research
The publication of clinical data from a Phase 1 trial of TPIV200, the company’s multi-epitope T-cell vaccine targeting Folate Receptor Alpha in patients with ovarian and breast cancer will be available online today.
TapImmune President & CEO, Peter Hoang, will be participating in two conferences next week.
TapImmune President & CEO, Peter Hoang, will be participating in two conferences in the upcoming weeks.
TapImmune President & CEO, Peter Hoang, to present at Biotech Showcase next week.
TapImmune Announces Enrollment of First Patient in Phase 2 Clinical Trial for Treating Triple-Negative Breast Cancer Funded by U.S. Department of Defense
“We remain grateful to the U.S. Department of Defense and Mayo Clinic for enabling TapImmune to gain invaluable clinical safety and efficacy insight for TPIV200 under this grant,” said TapImmune President and CEO Peter Hoang.
You can now view the presentation from last Thursday’s Virtual Investor Conference call.
Dr. Kenney will continue to manage the Company’s ongoing and planned clinical programs for its novel, multi-epitope, T-cell vaccine candidates.